AstraZeneca PLC
ZEG
Company Profile
Business description
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
Contact
1 Francis Crick Avenue
Cambridge Biomedical Campus
CambridgeCB2 0AA
GBRT: +44 2037495000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
96,100
Stocks News & Analysis
stocks
Chart of the Week: China demand for copper falls amidst record rally
Elevated copper prices raise valuation questions.
stocks
Reporting season was stronger than share prices suggest
What 164 ASX earnings results revealed.
stocks
How Anthropic makes money—and what investors should know ahead of its IPO filing
Part one of a two-part Q&A with PitchBook senior analyst Harrison Rolfes on Anthropic’s business model and why it needs to grow margins, fast.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,170.80 | 10.40 | 0.11% |
| CAC 40 | 8,280.63 | 21.22 | -0.26% |
| DAX 40 | 25,839.33 | 130.78 | -0.50% |
| Dow JONES (US) | 53,061.95 | 295.07 | 0.56% |
| FTSE 100 | 10,756.45 | 32.83 | -0.30% |
| HKSE | 25,520.07 | 208.86 | 0.83% |
| NASDAQ | 26,217.83 | 118.05 | 0.45% |
| Nikkei 225 | 64,326.16 | 0.52 | 0.00% |
| NZX 50 Index | 13,880.94 | 49.63 | -0.36% |
| S&P 500 | 7,666.60 | 35.13 | 0.46% |
| S&P/ASX 200 | 8,987.90 | 13.90 | 0.15% |
| SSE Composite Index | 3,961.85 | 20.47 | 0.52% |